A new study published in the prestigious journal Cell provides compelling evidence that autoantibodies may play a causal role in the neurological symptoms of Long COVID. CellTrend was also among the researchers.
They found that some patients develop elevated levels of autoantibodies targeting structures of the central and peripheral nervous system. In animal models, these antibodies induced symptoms resembling Long COVID, including fatigue, impaired coordination, increased pain sensitivity, and damage to small nerve fibers.
The findings suggest that neurological manifestations of Long COVID may, in a subset of patients, be driven by autoimmune mechanisms. This discovery represents an important step toward the development of targeted immunomodulatory therapies. However, further clinical studies are required before these findings can be translated into routine clinical practice. Here you will find more information.
